Delhi govt asks pharmacists to not sell painkillers without prescription

The Department of Drugs Control has advised chemists to avoid over-the-counter sale of NSAIDs such as aspirin, ibuprofen and diclofenac with immediate effect until further notice

medicine, drugs, painkiller
Photo: Shutterstock
BS Web Team New Delhi
2 min read Last Updated : Jul 20 2023 | 7:01 PM IST
The Department of Drugs Control, under the aegis of the Delhi government, has written a letter to the president of the All Chemist Associations of Delhi to avoid the sale of non-steroidal anti-inflammatory drugs (NSAIDs) without the prescription of a medical practitioner.

The department has advised chemists to avoid over-the-counter sales of NSAIDs such as aspirin, ibuprofen, and diclofenac with immediate effect until further notice.

The letter stated, "They (chemists) are also advised to keep records of stocks of painkiller drugs falling under this category. Stringent action will be taken against retail chemists, if found flaunting this advice."

According to department officials, these medicines destroy platelets in human blood.

With the rise of vector-borne diseases such as dengue and chikungunya in monsoons, taking these medicines without supervision could be harmful, they said.

In the letter, K R Chawla, a Controlling Authority official, said that there is a chance of vector-borne diseases rising in the pre-monsoon and post-monsoon periods, and close monitoring is required.

An official from the drugs control department said that such an advisory is issued every year, and it is more relevant this year because of the floods in Delhi.

Painkillers may lead to a decline in blood platelet count, and doctors generally caution against taking pain relievers without medical supervision.

The most common side effects of NSAIDS are indigestion, stomach ulcer, headache, drowsiness, dizziness, allergic reactions, kidney issues, heart attack, and strokes.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :painkillerAspirinibuprofenmedicinepharmacy

First Published: Jul 20 2023 | 7:01 PM IST

Next Story